Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Aptamer Solutions Ltd
Aptamer Solutions Ltd
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Drug Delivery
Aptamer and AstraZeneca to determine the efficacy of targeted siRNA delivery vehicle
AstraZeneca is providing Aptamer with siRNAs to test if its Optima fibrotic liver technology can successfully facilitate the delivery and cell integration of therapeutic RNA
Drug Delivery
Aptamer Group signs material agreement with genetic medicines company
Optimer binders will be developed to support targeted genetic medicines to specific cell types
Manufacturing
Aptamer and Neuro-Bio collaborate on Alzheimer’s disease diagnostic
The novel Alzheimer’s disease biomarker was discovered and is currently being further validated by Neuro-Bio, led by neuroscientist Baroness Susan Greenfield
Manufacturing
Aptamer launches reagent solution for immunohistochemistry
The Optimer-Fc is an antibody alternative for use within existing workflows replacing the primary, detecting, antibody
Drug Delivery
Aptamer partners with BaseCare Therapeutics
BaseCure Therapeutics is a pre-clinical stage biotech company dedicated to the discovery and development of innovative siRNA-based medicines
Manufacturing
Appointment of Interim Chief Commercial Officer, Aptamer Group
Derek joined the company in 2018 as Director of Global Sales
Drug Delivery
Aptamer Group's new deal supports novel therapies
Since the publication of the group’s full year results, the company has signed deals with a number of companies related to the development of Optimer solutions
Subscribe now